// App-Quantinova.ai

: Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study

Researchers

Presenter

  • Ian Naya

Principal Investigators

  • Helen Barnacle

  • Ruby Birk

  • Noushin Brealey

  • Maggie Tabberer

  • Chang-Qing Zhu

  • David Lipson

Medical Centers

  • GSK, Uxbridge, United Kingdom

  • CSL Behring, King of Prussia, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Catalase

  • Exostosin Glycosyltransferase 1

Drug/Treatment

  • fluticasone furoate/umeclidinium/vilanterol

  • budesonide + formoterol fuma

  • DuoResp Spiromax

  • Fluticasone furoate

  • Umeclidinium

  • Fluticasone

  • Budesonide

  • Formoterol

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved